Forbion, a Netherlands-based life sciences venture firm, raised €2.3 billion (about $2.6 billion) across two funds—its largest fundraising haul to date.
Eli Lilly is among the named backers, alongside Dutch pension investors MN and PGGM, Germany’s KfW Capital and the Kauffman Foundation. The raise included both existing and new investors.
The funds are Forbion Growth Opportunities Fund IV, focused on later-stage biopharma, and Forbion Ventures Fund VIII, focused on therapeutics companies at various stages.
Together, the funds could support around 30 companies; Forbion says it has already made initial investments. The fundraising brings the firm’s assets under management to about €7.5 billion.
The reported total exceeds the roughly €2.09 billion raised for the two predecessor funds combined.
Sources:
Eli Lilly, PGGM and KfW Capital back Forbion's €2.3B fund for 30 biotechs — TFN
Forbion, a prominent biotech investor, raises $2.6B for ...
Forbion raises $2.6 billion across two new biotech funds
Forbion tops predecessor haul with €2.3bn dual fundraise - Alternatives Watch
Forbion raises €2.3bn, now Europe's top biotech investor - DutchNews.nl
Forbion raises €2.3bn, now Europe's top biotech investor - DutchNews.nl
Forbion's 'landmark' €2.3B fundraise to benefit 30 biotechs
Forbion raises $2.6B for biotech investments, its largest ...
Forbion Funds New Medicines. Its Buyers Say Europe Is Losing
Forbion Raises $2.6 Billion in Boost to European Biotech ...
Netherlands: Forbion raises €2.3bn across two new life sciences venture funds
Recon: BD pledges $19B US investment; McKesson, CD&R to buy Option Care for $5.8B
Forbion Bucks VC Fundraising Trends, Reeling In €2.3B for ...